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TO THE EDITOR
The problem of how to cure P190 BCR-ABL+ as well as P210 BCR-ABL+ acute lymphoblastic leukemia (ALL) patients still remains unsolved. Encouraging results have been reported with the use of imatinib mesylate (STI571) (Novartis, Basel, Switzerland) that has shown efficacy in both CML and Ph + ALL. 1, 2 The duration of the response, however, has been short in the majority of acute phase CML as well as Ph + ALL. A combination of imatinib mesylate with biological response modifiers could be a possibly successful option. In particular, ␣-IFN has shown efficacy in maintaining remission if administered to P190
BCR-ABL+ ALL patients, with long-lasting control of the disease. 3 Based on this, we tested the in vivo effect of imatinib mesylate and ␣-IFN in combination in a patient affected by P190
BCR-ABL+ ALL, in a third relapse after previous successful reinductions of remission with ␣-IFN and imatinib mesylate as single treatments, tailoring the effects of the combination with qualitative RT-PCR and real time RT-PCR transcript quantification.
A 45-year-old woman was referred with acute lymphoblastic leukemia (ALL) in May 1990. Cytogenetic analysis was apparently normal. The patient received a remission induction chemotherapy cycle according to a modified L-20 regimen. Briefly, this consisted of vincristine 2.0 mg/m 2 weekly (weeks 1 to 5), 6-methylprednisolone 60 mg/m 2 /d (days 1-32), cyclophosphamide 1000 mg/m 2 (day 4) and 800 mg/m 2 (day 32), adriamycin 30 mg/m 2 (days 15-18 and day 32). Prophylactic central nervous system treatment with dexamethasone, cytosine-arabinoside and methotrexate was administered weekly. After a morphological complete remission (CR) was achieved in July 1990, the patient was submitted to a rotational consolidation regimen for 1 year (starting August 1990, ending August 1991), followed by a standard maintenance treatment with cycles of methotrexate/6-mercaptopurine (6 weeks duration) alternated with periodical L-20 reinduction (vincristine/6-methylprednisolone). This treatment was administered continuously for up to 2 years from the first demonstration of CR. In April 1997 the patient experienced a morphological relapse. Cytogenetic analysis was apparently normal, whereas the presence of a distinctive P190 BCR-ABL fusion protein was detected with molecular biology. An identical L-20 reinduction cycle was administered, obtaining a second CR in May 1997. Autologous peripheral blood stem cell transplantation (ASCT) was performed in September 1997 with busulphan 4/mg/kg/day (4 days) and cyclophosphamide 60 mg/kg/day (2 days) as a conditioning regimen. The ASCT was followed by a maintenance treatment with cycles of ␣-IFN (Roferon-␣; Roche, Milan, Italy) 3 MU, three times a week for 6 weeks (subcutaneous injection), alternating with metothrexate 70 mg/m 2 /day and 6-mercaptopurine 30 mg/m 2 /weekly for 6 weeks duration, administered continuously for 1 year. Afterwards, the patient was treated with ␣-IFN alone with the same schedule (6 weeks on, 6 weeks off) without interruption until morphological CR was maintained. with a reduction of the number of transcript copies for the Bcr-Abl fusion transcript to a level well below that seen both in CML patients, as well as in the same patient during the previous treatments with ␣-IFN or imatinib mesylate. Until now, after 18 months of combined treatment, the patient is in a complete morphological and molecular CR (see Figure 1) . The combined treatment has been well tolerated, with only minor side-effects (nausea, vomiting, perimalleolar edema).
Treatment of Ph + acute lymphoblastic leukemia patients remains problematic. Although intensified induction regimens result in complete remission rates of nearly 70%, the incidence of relapse is extremely high even when strategies based on intensive chemotherapy or autologous stem cell transplantation (ASCT) are adopted. Despite this, isolated long-term survivors have been described. 3 Thus, the problem is not so much how to obtain CR, but how to maintain remission and how to find treatments which are both tolerable and effective for relapsed patients. Until now, the only available curative option has been allogeneic bone marrow transplantation.
Bcr-abl is a constitutively activated tyrosine kinase that has been shown to be the cause of CML, as well as of Ph + ALL, with tyrosine kinase activity being essential to the function of the Bcr-Abl protein. 5, 6 Recent clinical trials with imatinib mesylate, a drug that specifically inhibits the Bcr-Abl tyrosine kinase, have shown efficacy in both CML and Ph + ALL. 1,2 The duration of response, however, has been short in the majority of cases of acute phase CML as well as Ph + ALL, confirming that relapse is still a major problem even with imatinib mesylate. 1 Both the previous heavy pretreatment and the high resistance to chemotherapy of relapsed Ph + ALL produce a disease that responds poorly to further intensive treatment. Therefore, a combination of imatinib mesylate with biological response modifiers could be a successful option, providing an additive or synergistic effect. Biological response modifiers, such as IFN or interleukin-2 have been suggested for Ph + ALL patients. In particular, ␣-IFN has shown efficacy in main-
Figure 1 P190 BCR-ABL
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Leukemia taining remission if administered to P 190BCR-ABL -positive ALL patients, with long lasting control of the disease. 3 The efficacy of ␣-IFN as a front-line therapy in relapsed patients is still unknown. On the other hand, it has been recently reported that the combination of imatinib mesylate with ␣-IFN in proliferating assays in vitro (Bcr-Abl-positive cell lines and colony-forming assays generated from CML cells) has shown additive effects. 7 It is in particular noteworthy that all the patients whose samples were used in colony-forming assays had failed a trial of ␣-IFN alone, with perhaps an underestimation of the effects of the imatinib mesylate/␣-IFN combination.
Based on these biological and clinical premises, we successfully reinduced a complete morphological, cytogenetic and molecular remission in a P 190BCR-ABL+ patient who had previously proved sensitive to imatinib mesylate and ␣-IFN used as single agents, and had subsequently re-experienced a relapse to both drugs. The combination proved effective in a short period of time (49 days) and is to date (18 months) well tolerated. Interestingly, the qualitative PCR, that was persistently positive during the CR period induced by ␣-IFN, as well as during imatinib mesylate treatment, showed a negativization of the transcript during the combined treatment, starting from the first determination and persisting to date. Real time RT-PCR confirmed this result, showing a reduction of the number of copies of the bcr-abl fusion transcript during the combined treatment, well below the threshold line of the CML analyzed patients, 4 as well as of the data obtained during previous treatments in the same patient with ␣-IFN or imatinib mesylate as single treatment (Figure1) . Thus, the combination not only proved effective in reinducing long-lasting continuous complete remission, but the quality of molecular remission was improved when compared to the previous treatments with single drugs, notwithstanding the more advanced state of the disease at the time of administration of the combination. Whether the biological and clinical effects of this combination are due to activation of different pathways, or to a reversal of the previous clinical resistance to each drug, is still unknown and worthy of investigation. It is interesting to note, however, that both drugs have been demonstrated to activate different apoptotic pathways in Ph + blastic crisis cell lines, namely Fas/Fasl and TRAIL induced by ␣-IFN and a direct apoptotic effect with imatinib mesylate, which could be possible reasons for their additive anti-leukemic effect. Further studies are warranted to elucidate the mechanism of this enhancement. Anyway, these data suggest that clinical trials with this combination are worth pursuing in patients with Ph + ALL, in particular if heavily pretreated, or with no available HLA compatible donor. effects of imatinib mesylate on the liver have been reported, histologic examination in Ph-positive leukemia patients who are treated with imatinib mesylate is not performed. Here we report on a CML patient with hepato-toxicity that may be induced by imatinib mesylate.
The patient was a 56-year-old female who was first diagnosed as having CML in May 1989. She was treated with hydroxyurea until September 1995, and then treated with interferon-␣ (3 Meg natural interferon-␣) until January 2002. Interferon-␣ treatment resulted in a major cytogenetic response; marrow cytogenetics using a BCR/ABL FISH analysis detected 28.1% fusion gene in October 2001. She has been treated with interferon-␣ for more than 7 years without complete cytogenetic response. Therefore, imatinib mesylate (400 mg/day, p.o.) was started on 1 February 2002. Before administration of imatinib mesylate, her white blood cell count was 2 × 10 9 /l, including 77% neutrophils, a hemoglobin of 117 g/l, and a platelet count of 178 × 10
